Choice of drug treatment for obesity-related hypertension: Where is the evidence?

Journal of Hypertension

Volumn 19, Issue 4, 2001, Pages 667-674

  Sharma, Arya M ^a,b   Pischon, Tobias ^a,b   Engeli, Stefan ^a,b   Scholze, Juergen ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Body weight; Hypertension; Obesity; Therapy; Treatment; Weight gain

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; VERAPAMIL;

BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

EID: 0035072525     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200104000-00001     Document Type: Review

References (95)

1. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
2. Assessing obesity: Classification and epidemiology
3. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
4. 1999 World Health Organization-International Society of hypertension guidelines for the management of hypertension
5. Obesity and heart disease: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
6. Secular blood pressure trends in normotensive persons: The Framingham study
7. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study
8. Obesity-induced hypertension: New concepts from the emerging biology of obesity
9. Obesity and hypertension
10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
11. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38
12. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
13. Metabolic considerations in the choice of therapy for the patient with hypertension
14. Metabolic considerations in hypertension
15. Dimorphic cardiac adaptation to obesity and arterial hypertension
16. Microalbuminuria in obese patients with or without hypertension
17. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss
18. Predicting sudden death in the population: The Paris Prospective Study I
19. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity
20. Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community
21. Cardiovascular regulation in obesity-induced hypertension
22. Obesity and the sympathetic nervous system
23. Obesity, the sympathetic nervous system, and essential hypertension
24. Mechanisms of hypertension and kidney disease in obesity
25. Obesity and beta-blockers: Influence of body fat on their kinetics and cardiovascular effects
26. Verapamil pharmacodynamics and disposition in obese hypertensive patients
27. A comparison of the effects of hydrochlor-othiazide and captopril on glucose and lipid metabolism in patients with hypertension
28. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure
29. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A multicenter placebo-controlled trial
30. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
31. Effect of antihypertensive therapy on weight loss
32. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
33. Obesity as a determinant for response to antihypertensive treatment
34. Obesity and cardiovascular hemodynamic function
35. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
36. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
37. Beta adrenergic receptor blockers and weight gain: A systematic analysis
38. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol
39. Carbohydrate metabolism in hypertension: Influence of treatment
40. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients
41. Diabetes mellitus in treated hypertension: Incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden
42. Calcium-antagonist drugs
43. Calcium antagonists and the kidney
44. Obesity hypertension. Converting enzyme inhibitors and calcium antagonists
45. Body fat as a predictor of the antihypertensive effect of nifedipine
46. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension
47. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension
48. A comparison of the effects of nifedipine and verapamil on exercise performance in patients with mild to moderate hypertension
49. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure
50. Preservation of renal function: The spectrum of effects by calcium-channel blockers
51. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
52. Effects of antihypertensive therapy on hypertensive heart disease
53. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captepril Prevention Project (CAPPP) randomised trial
54. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
55. Physiology and pathophysiology of the adipose tissue renin-angiotensin system
56. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension
57. Effects of inhibition of the renin - Angiotensin system on the cardiovascular actions of insulin
58. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients
59. Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol
60. Plasma viscosity, fibrinogen and the metabolic syndrome: Effect of obesity and cardiorespiratory fitness
61. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
62. Drug treatment of hypertension in patients with diabetes mellitus
63. Doxazosin effects on insulin and glucose in hypertensive patients
64. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension
65. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
66. From hypertension to heart failure: What have we learned?
67. Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine
68. Oral clonidine premeditation decreases energy expenditure in human volunteers
69. Effect of clonidine on the thermic effect of feeding in humans
70. Obesity and hypertension: From pathophysiology to treatment
71. Effects of nonpharmacological intervention on insulin sensitivity
72. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial - The Hypertension Control Program
73. Lifestyle intervention in overweight individuals with a family history of diabetes
74. Long-term follow-up of behavioral treatment for obesity: Patterns of weight regain among men and women
75. Mode of action of orlistat
76. Treatment with orlistat reduces cardiovascular risk in obese patients
77. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
78. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
79. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1 -year randomized double-blind study
80. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
81. Sibutramine produces dose-related weight loss
82. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
83. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1 -year, double-blind, placebo-controlled, multicenter trial
84. Sibutramine's effects on ventricular dimensions and heart valves in obese patients during weight reduction
85. Thermogenic effects of sibutramine in humans
86. The natriuretic peptide system in obesity-related hypertension: New pathophysiological aspects
87. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients
88. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
89. Plasma endothelin-1 levels in obese hypertensive and normotensive men
90. Central obesity and hypertension. The role of plasma endothelin
91. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs
92. Pharmacogenomics of hypertension: A realizable goal?
93. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
94. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
95. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study